Status:
COMPLETED
Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
FEMALE
18-60 years
Phase:
PHASE2
Brief Summary
NRG1 gene fusions are extremely rare across solid tumours (estimate 0.3-0.5%). However, it is felt to be an actionable and potentially major growth pathway for those tumours that harbour this gene rea...
Eligibility Criteria
Inclusion
- Serious, life-threatening condition
- Not eligible for, or exhausted all other treatment options or causing significant toxicity
- No other way to access treatment
Exclusion
- \-
Key Trial Info
Start Date :
March 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2021
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04790695
Start Date
March 29 2021
End Date
December 22 2021
Last Update
January 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6